E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Persistent Asthma in adults |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10049106 |
E.1.2 | Term | Asthma chronic |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Comparison of efficacy and safety of fluticasone propionate 250 µg via a novel DPI versus fluticasone propionate 250 µg via Accuhaler TM / Diskus® in patients with moderate persistent asthma
Primary efficacy criterion: Change in the forced expiratory volume in 1 second [FEV1] between baseline (day 0) and end of treatment (day 56) |
|
E.2.2 | Secondary objectives of the trial |
Secondary efficacy criteria: Change in other spirometric parameters, including forced vital capacity (FVC) and FEV1/FVC, FEF25% and FEF25-75% Morning and evening PEFR, recorded daily by the patient Day-time and night-time asthma symptom scores, recorded daily by the patient Need of short-acting Beta2-agonist use Global assessment of efficacy by investigators and patients
Criteria for safety evaluation: Changes in clinical laboratory and ECG between baseline and end of treatment Changes in cortisol level (blood, urine) between baseline and end of treatment Vital signs at each visit: heart rate, blood pressure Signs of oropharyngeal candidiasis at each visit under treatment Assessment of cough, wheezing and bronchospasm following inhalation Assessment of other adverse events
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Men or women aged between 18 and 65 years 2. Written informed consent 3. Current diagnosis of persistent asthma according to generally acknowledged criteria 4. For the period of 4 weeks prior to screening: No intake of inhaled corticosteroids or daily regimen of inhaled corticosteroids in a low daily dose of 200 to 400 µg budesonide or equivalent* 5. A forced expiratory volume in one second (FEV1) of less than 80% of the predicted value or personal best (if known) 6. Need for retriever/ rescue treatment at least twice/ week or occurrence of day-time asthmatic symptoms more than twice/ week 7. Documented FEV1-reversibility of equal to or more than 12% (or equal to or more than 200 ml) from the pre-bronchodilator value 8. Capable of understanding the directions for device usage
|
|
E.4 | Principal exclusion criteria |
1. Respiratory tract infection equal to or less than 6 weeks prior to study entry 2. Acute asthma attack, which led to hospitalisation equal to or less than 1 month prior to study entry 3. Smokers equal to or less than 6 weeks prior to study entry 4. History of cystic fibrosis or bronchiectasis 5. Known hypersensitivity to fluticasone propionate or lactose 6. Need of more than 8 puffs of 200 µg salbutamol on a daily base 7. Previous treatment with oral, parenteral or depot corticosteroids equal to or less than 1 month prior to study entry 8. Daily regimen of inhaled long-acting beta-agonists (LABA) like formoterol or salmeterol equal to or less than 4 weeks prior to study entry 9. Previous treatment equal to or less than 1 month prior to study entry or concomitant treatment with substances which may decrease the efficacy of the test substance(s) or may lead to drug interactions, as for example strong inhibitors of the cytochrome 450 3A system like ketoconazole, ritonavir or erythromycine 10. Clinically significant conditions that might compromise patient safety, patient compliance, interfere with evaluations or preclude completion of the trial, like diabetes mellitus or hyperthyroidism, not adequately controlled 11. Severe cardiovascular, hepatic or renal disorders 12. Abnormal 12-lead ECG at screening recorded after at least 5 min of rest in supine position 13. Acute and/ or serious diseases (e.g. existing malignancy, known HIV-infection, untreated infections) 14. Women of childbearing potential should either be surgically sterile (hysterectomy or tubal ligation), or should use a medically accepted contraceptive regimen: systemic contraceptive (oral, implant, injection), diaphragm or cervical cap with intravaginal spermicide, intrauterine device (IUD), condom with intravaginal spermicide 15. Pregnancy or lactation 16. History of alcohol and/or drug and/or substance abuse 17. Unwilling or unable to provide informed consent or to participate satisfactorily for the entire trial period 18. Current participation in another clinical study or former participation in this study
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Primary efficacy criterion: Change in the forced expiratory volume in 1 second [FEV1] between baseline and end of treatment |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 10 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |